Compare JPMorgan Equity Premium Income ETF (JEPI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Novartis AG — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.73 (market cap $45.55B), while Novartis AG trades at $143.49 (market cap $268.57B). The key difference: Novartis AG is far larger — about 5.9× JPMorgan Equity Premium Income ETF's market cap, and Novartis AG pays a 3.31% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 56 Days and Novartis AG for 82 Days on average.
| JEPI | NVS | |
|---|---|---|
Market Cap | $45.55B | $268.57B |
Volume | 3,820,809 | 1,532,573 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $168.62 |
52-Week Low | $55.29 | $121.80 |
Typical Hold Time | 56 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.45, down 0.16% with a bearish technical outlook. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.37 in August and September 2026. Technical indicators show bearish momentum with selling pressure in moving averages, while oscillators remain neutral. The fund continues to attract income-focused investors seeking monthly payouts through its covered call strategy.
The outlook remains cautious given the bearish technical signals and market volatility. Income investors may find value in the consistent dividend stream, but capital appreciation potential appears limited in the current technical environment. Key risks include market direction sensitivity and interest rate impacts on income strategies.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
